Exeliom Biosciences Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $3.33M

  • Investors
  • 17

Exeliom Biosciences General Information

Description

Developer of immunotherapies designed to help harness the therapeutic potential of gut microbiota. The company develops single-bacterial-strain drug candidates to deliver microbiome-based immunotherapy for treating inflammatory bowel diseases and cancer, starting with Crohn's Disease as a first indication, enabling patients to lead longer and healthier lives by accessing medicines derived from the microbiota.

Contact Information

Website
www.exeliombio.com
Formerly Known As
Nextbiotix
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 19 Rue de choiseul
  • 75002 Paris
  • France
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 19 Rue de choiseul
  • 75002 Paris
  • France

Exeliom Biosciences Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Exeliom Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series A) 21-Oct-2025 $3.33M Completed Clinical Trials - Phase 2
6. Grant 04-Mar-2024 Completed Clinical Trials - Phase 1
5. Later Stage VC 30-Jun-2023 Completed Clinical Trials - Phase 1
4. Secondary Transaction - Private Completed Clinical Trials - Phase 1
3. Grant 03-Aug-2020 Completed Clinical Trials - Phase 1
2. Grant 12-Aug-2019 $2.01M $3.98M Completed Clinical Trials - Phase 1
1. Seed Round 11-Dec-2018 $3.98M $3.98M Completed Startup
To view Exeliom Biosciences’s complete valuation and funding history, request access »

Exeliom Biosciences Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
A Shares
To view Exeliom Biosciences’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Exeliom Biosciences Patents

  • 19

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 12

    Pending

  • Expiring in next 12 mo

Exeliom Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026132395-A2 Muropeptides and peptidoglycans, and their use in the treatment of diseases Pending 19-Dec-2024
WO-2026132395-A3 Muropeptides and peptidoglycans, and their use in the treatment of diseases Pending 19-Dec-2024
AU-2023413727-A1 Faecalibacterium prausnitzii strain cncm i-4573 for the treatment and prevention of clostridioides difficile infection Pending 20-Dec-2022
EP-4389134-A1 Faecalibacterium prausnitzii strain cncm i-4573 for the treatment and prevention of clostridioides difficile infection Inactive 20-Dec-2022
EP-4637795-A1 Faecalibacterium prausnitzii strain cncm i-4573 for the treatment and prevention of clostridioides difficile infection Pending 20-Dec-2022 A61K35/741
To view Exeliom Biosciences’s complete patent history, request access »

Exeliom Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Exeliom Biosciences Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
CresVentures Angel Group Minority
Crohn's & Colitis Foundation Limited Partner
Auriga Partners (Paris) Venture Capital Minority
Capital Grand Est PE/Buyout Minority
CE-Ventures Corporate Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

Ready to get started?

Request a free trial

Exeliom Biosciences FAQs

  • When was Exeliom Biosciences founded?

    Exeliom Biosciences was founded in 2016.

  • Where is Exeliom Biosciences headquartered?

    Exeliom Biosciences is headquartered in Paris, France.

  • What is the size of Exeliom Biosciences?

    Exeliom Biosciences has 8 total employees.

  • What industry is Exeliom Biosciences in?

    Exeliom Biosciences’s primary industry is Drug Discovery.

  • Is Exeliom Biosciences a private or public company?

    Exeliom Biosciences is a Private company.

  • What is Exeliom Biosciences’s current revenue?

    The current revenue for Exeliom Biosciences is .

  • How much funding has Exeliom Biosciences raised over time?

    Exeliom Biosciences has raised $33.3M.

  • Who are Exeliom Biosciences’s investors?

    CresVentures, Crohn's & Colitis Foundation, Auriga Partners (Paris), Capital Grand Est, and CE-Ventures are 5 of 17 investors who have invested in Exeliom Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process